期刊文献+

大肠癌组织中NF-κB p65的活化与k-ras基因突变的相关性研究

Relationship between NF-κB p65 activation and k-ras gene mutation in colorectal cancer
原文传递
导出
摘要 目的 探讨大肠癌组织中NF-κB p65的活化与k-ras基因突变的相关性。方法 用免疫组织化学方法检测167例已知k-ras基因状态的大肠癌组织中NF-κB p65的核表达。结果 在167例大肠癌组织中,k-ras基因突变59例,突变率35.3 %;NF-κB p65核表达阳性63例,阳性率37.7 %。不同性别、年龄、ECOG评分、病理类型、病理分化程度、TNM分期、淋巴结转移与否的病例k-ras基因突变率和NF-κB p65核表达差异均无统计学意义(均P>0.05)。k-ras基因突变的病例中NF-κB p65核表达率50.8 %(30/59),k-ras基因野生型病例中NF-κB p65核表达率30.6 %(33/108)。两者的表达率差异有统计学意义(P=0.010)。结论 大肠癌组织中NF-κB p65的活化与k-ras基因突变相关。 Objective To investigate the corresponds between NF-κB p65 activation and k-ras mutations. Methods NF-κB p65 activation was analyzed by immunochemistry in 167 colorectal cancer specimens in which the k-ras mutation status was confirmed. Resluts Among 167 colorectal cancer specimens screened , 59 (35.3 %) had k-ras mutations and 63 (37.7 %) had NF-κB p65 activation. k-ras mutations and NF-κB p65 nuclear expression were no significant difference in different sex, age, ECOG score, pathological types, degrees of pathological differentiation, TNM stage, and metastases on lymph nodes (P 〉 0.05). The positive nuclear expression rate of NF-κB p65 was 50.8 % (30/59) in specimens with k-ras mutations and 30.6 % (33/108) in specimens with wild type k-ras. There was obviously statistical difference between them (P = 0.010). Conclusion NF-κB p65 activation in coloretal cancer was associated with k-ras mutations.
出处 《肿瘤研究与临床》 CAS 2013年第8期513-515,526,共4页 Cancer Research and Clinic
基金 福建省自然科学基金(2012J01327) 福建省卫生厅青年科研课题(2010-2-37)
关键词 肠肿瘤 NF-ΚB P65 免疫组织化学 K-RAS Colorectal cancer NF-κB p65 Immunochemistry k-ras
  • 相关文献

参考文献16

  • 1Christian M,Michalis PC,Upinder B,et al.Expression of cyclooxygenase-2 parallels expression of interleukin-1 beta,interleukin-6 and NF-κB in human colorectal cancer.Carcinogenesis,2003,24:665.
  • 2Lievre A,Bachet JB,Boige V,et al.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab.J Clin Oncol,2008,26:374-379.
  • 3Camp RR,Li J,Minnich DJ,et al.Inducible NF-κB activation contributes to chemotherapy resistance in gastric cancer.J Am Coll Surg,2004,199:249-258.
  • 4Kojima M,Morisaki T,Sasaki N,et al.Increased NF-κB activation in human colorectal carcinoma and its correlation with tumor progression.A nticancer Res,2004,24:675-681.
  • 5Izzo JG,Malhotra U,Wu TT,et al.Association of activated factor NF-κ B with chemoradiation resistance and poor outcome in esophageal carcinoma.J Clin Oncol,2006,24:748-754.
  • 6Wong KK,Jacks T,Dranoff G.NF-kappaB fans the flames of lung carcinogenesis.Cancer Prey Res (Phila),2010,273:403-405.
  • 7Finco TS,Westwick JK,Norris JL,et al.Oncogenic Ha-Rasinduced signaling activates NF-kappaB transcriptional activity,which is required for cellular transformation.J Biol Chem,1997,272:24113-24116.
  • 8Scartozzi M,Bearzi I,Pierantoni C,et al.NF-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.J Clin Oncol,2007,25:3930-3935.
  • 9Shen Y,Ye Y,Zheng X,et al.KRAS mutations in the plasma of colorectal cancer patients.Lab Med,2010,41:156-158.
  • 10Sen R,Baltimore D.Multiple nuclear factors interact with the immunoglobulin enhancer sequence.Cell,1986,46:705.

二级参考文献6

  • 1Van Cutsem E,K(o)hne CH,Hitre E,et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N Engl J Med,2009,360:1408-1417.
  • 2Dieterle CP,Conzelmann M,Linnemann U,et al.Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissure samples of 199 colorectal cancer patients.Clin Cancer,2004,10:641-650.
  • 3Brink M,de Goeij AF,Weijenberg MP,et al.K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study.Carcinogenesis,2003,24:703-710.
  • 4Karapetis CS,Khambata-Ford S,Jonker DJ,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med,2008,359:1757-1765.
  • 5Gormally B,Vineis P,Matullo G,et al.TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence:a prospective study.Cancer Res,2006,66:6871-6876.
  • 6Di Nicolantonio F,Martini M,Molinari F,et al.Wild-type BRAF is required for response to pantitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol,2008,26:5705-5712.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部